OPKO Health Inc.

Declaration of Voting Results & Voting Rights Announcements • Apr 24, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2025

OPKO Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-33528				75-2402409
(State or Other Jurisdiction	(Commission				(IRS Employer
of Incorporation)	File Number)				Identification No.)
	4400 Biscayne Blvd.	Miami,	Florida	33137
	(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (305) 575-4100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	OPK	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.07. Submission of Matters to a Vote of Security Holders.

On April 23, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Below is a summary of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting and the corresponding votes.

1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows:

Election of Directors	For	Against	Abstain	Broker Non Votes
Phillip Frost, M.D.	434,964,129	15,405,532	398,538	76,193,825
Jane H. Hsiao, Ph.D.	437,774,692	12,596,864	396,643	76,193,825
Elias A. Zerhouni, M.D.	434,808,543	15,565,748	393,908	76,193,825
Steven D. Rubin	431,540,459	18,851,054	376,686	76,193,825
Gary J. Nabel, M.D., Ph.D.	433,141,213	17,199,627	427,359	76,193,825
Richard M. Krasno, Ph.D.	442,890,267	7,401,828	476,104	76,193,825
Prem A. Lachman, M.D.	444,341,039	5,584,697	842,463	76,193,825
Roger J. Medel, M.D.	444,507,113	5,408,979	852,107	76,193,825
John A. Paganelli	428,765,752	21,193,856	808,591	76,193,825
Richard C. Pfenniger, Jr.	444,585,339	5,672,331	510,529	76,193,825
Alice Lin-Tsing Yu, M.D., Ph.D.	444,805,156	5,495,434	467,609	76,193,825

1. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company's 2025 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows:

For	Against	Abstain	Broker Non Votes
439,260,125	10,995,027	513,047	76,193,825

1. The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes on this proposal were as follows:

For	Against	Abstain	Broker Non Votes
522,666,577	3,921,683	373,764	0

No other matters were considered or voted upon at the meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By: /s/ Steven D. Rubin

Date: April 23, 2025 Name: Steven D. Rubin Title: Executive Vice President - Administration